Objective To investigate the effect of arbutin(Arb)on osteogenic differentiation of human periodontal ligament stem cells(hPDLSCs)under inflammatory conditions and the mechanism of NF-κB signaling pathway in this process.Methods The effects of Arb on the proliferation and osteogenic differentiation of hPDLSCs were analyzed by CCK-8,alkaline phosphatase staining,Alizarin Red staining,and Western blot.After establishing an inflammatory model using lipopolysaccharide(LPS),the effect of Arb on the ex-pression levels of inflammatory factors in hPDLSCs was analyzed by RT-qPCR.The effect of Arb on osteogenic differentiation of hP-DLSCs was analyzed,and the effect of Arb on the NF-κB pathway was analyzed by Western blot.After adding the NF-κB signaling pathway activator PMA to the culture system,whether the effect of Arb on hPDLSCs changed was analyzed.Results 100 nmol/L Arb did not affect the proliferation of hPDLSCs,but significantly promoted cell osteogenic differentiation and inhibited the expression of in-flammatory factors under LPS stimulation.Arb reduced the activation effect of LPS on the NF-κB signaling pathway and the inhibitory effect on cell osteogenic differentiation,while the efficacy of Arb was partially eliminated by PMA.Conclusion Arb alleviates the in-hibitory effect of LPS on osteogenic differentiation of hPDLSCs by inhibiting NF-κB signaling.

Objective To investigate the effect of arbutin(Arb)on osteogenic differentiation of human periodontal ligament stem cells(hPDLSCs)under inflammatory conditions and the mechanism of NF-κB signaling pathway in this process.Methods The effects of Arb on the proliferation and osteogenic differentiation of hPDLSCs were analyzed by CCK-8,alkaline phosphatase staining,Alizarin Red staining,and Western blot.After establishing an inflammatory model using lipopolysaccharide(LPS),the effect of Arb on the ex-pression levels of inflammatory factors in hPDLSCs was analyzed by RT-qPCR.The effect of Arb on osteogenic differentiation of hP-DLSCs was analyzed,and the effect of Arb on the NF-κB pathway was analyzed by Western blot.After adding the NF-κB signaling pathway activator PMA to the culture system,whether the effect of Arb on hPDLSCs changed was analyzed.Results 100 nmol/L Arb did not affect the proliferation of hPDLSCs,but significantly promoted cell osteogenic differentiation and inhibited the expression of in-flammatory factors under LPS stimulation.Arb reduced the activation effect of LPS on the NF-κB signaling pathway and the inhibitory effect on cell osteogenic differentiation,while the efficacy of Arb was partially eliminated by PMA.Conclusion Arb alleviates the in-hibitory effect of LPS on osteogenic differentiation of hPDLSCs by inhibiting NF-κB signaling.

Objective: To analyze the efficacy of HLA-haploidentical peripheral hematopoietic stem cell transplantation (haplo-PBSCT) following reduced intensity conditioning (RIC) regimen to treat the patients with hematological malignancies who were older than 50 years old. Methods: Eighteen patients with hematological malignancies over 50 years were enrolled, including 8 male and 10 female patients. The median age of all patients was 52 (range: 50–66) years. Of them, 8 patients had acute myeloid leukemia (AML) , 2 chronic myelocytic leukemia (CML) , 5 myelodysplastic syndrome (MDS) , 2 acute lymphoblastic leukemia (ALL) , and 1 aggressive natural killer cell leukemia (ANKL) . All patients received fludarabine, cytarabine and melphalan with rabbit anti-human thymocyte globulin (FAB+rATG regimen) and transplanted with high dose non-T cell-depleted peripheral hematopoietic stem cells from donors. Enhanced graft versus host disease (GVHD) prophylaxis and infection prevention were administered. Results: Fifteen days after transplantation, 16 patients achieved complete donor chimerism. One of them rejected the donor graft completely at thirty days after transplantation, and the other 2 patients had mixed chimerism 15 days after transplantation and converted to complete recipient chimerism at 30 days after transplantation. The cumulative incidence of acute GVHD (aGVHD) was 61.1% (95%CI49.6%-72.6%) . The incidence of grade Ⅱ-Ⅳ aGVHD was 35.4% (95%CI 21.1%-49.7%) , whereas grade III-IV was 13.8% (95%CI 4.7%-22.9%) . The 2-year cumulative incidence of chronic GVHD (cGVHD) rate was estimated at 38.2% (95%CI 25.5%-50.9%) . Patients were followed-up for a median of 14.5 months (range, 3-44 months) . The Kaplan Meier estimates of 2-year overall survival (OS) and disease-free survival (DFS) was 72.6% (95%CI 60.1%-85.1%) and 63.7% (95%CI 49.2%-78.2%) , respectively. The 2-year cumulative incidence of relapse and non-relapse-mortality (NRM) was 31.2% (95%CI 16.5%-45.9%) and 12.5% (95%CI 4.2%-20.8%) , respectively. Conclusion RIC-haplo-PBSCT protocol can achieve better results in patients with hematologic malignancies over 50 years old.